Inozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by Wedbush

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research report issued on Tuesday, RTT News reports. They currently have a $15.00 target price on the stock. Wedbush’s target price would indicate a potential upside of 223.28% from the company’s previous close.

INZY has been the subject of a number of other reports. Bank of America reduced their price objective on shares of Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research note on Tuesday, April 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a research note on Wednesday, March 13th.

Inozyme Pharma Trading Up 0.9 %

Inozyme Pharma stock opened at $4.64 on Tuesday. The firm has a 50-day moving average of $5.62 and a 200-day moving average of $4.75. Inozyme Pharma has a one year low of $2.69 and a one year high of $7.80. The company has a debt-to-equity ratio of 0.32, a current ratio of 13.36 and a quick ratio of 13.36. The company has a market cap of $287.03 million, a price-to-earnings ratio of -3.34 and a beta of 1.54.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). On average, equities analysts expect that Inozyme Pharma will post -1.46 earnings per share for the current fiscal year.

Insider Activity at Inozyme Pharma

In other Inozyme Pharma news, CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the transaction, the chief executive officer now directly owns 20,665 shares of the company’s stock, valued at approximately $143,415.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 11.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Eventide Asset Management LLC raised its holdings in Inozyme Pharma by 1.8% in the 4th quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock valued at $13,546,000 after acquiring an additional 54,837 shares during the period. Superstring Capital Management LP bought a new position in Inozyme Pharma in the 4th quarter valued at about $528,000. Affinity Asset Advisors LLC raised its holdings in Inozyme Pharma by 36.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,885,802 shares of the company’s stock valued at $8,034,000 after acquiring an additional 505,950 shares during the period. Values First Advisors Inc. bought a new position in Inozyme Pharma in the 4th quarter valued at about $59,000. Finally, SG Americas Securities LLC raised its holdings in Inozyme Pharma by 46.9% in the 4th quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock valued at $90,000 after acquiring an additional 6,784 shares during the period. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.